FDA FINAL CME POLICY ALLOWS GENERAL STATEMENT ON OFF-LABEL USES INSTEAD OF DISCLOSURE FOR EACH USE DISCUSSED; WRITTEN AGREEMENTS LESS EMPHASIZED